$24.75
-0.98 (-3.81%)
Open$25.83
Previous Close$25.73
Day High$26.34
Day Low$24.40
52W High$50.81
52W Low$16.50
Volume—
Avg Volume1.52M
Market Cap1.27B
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+83.3% upside
Current
$24.75
$24.75
Target
$45.36
$45.36
$37.53
$45.36 avg
$61.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 117.09M | 98.00M | 574.93M |
| Net Income | -163,708,752 | -123,315,933 | 29.33M |
| Profit Margin | -139.8% | -132.8% | 5.1% |
| EBITDA | -132,846,258 | -105,627,674 | 65.79M |
| Free Cash Flow | — | — | 30.48M |
| Rev Growth | +19.5% | +19.5% | -7.8% |
| Debt/Equity | — | — | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |